{"frequencyBands":{"HP:0040280":[100,100],"HP:0040281":[80,99],"HP:0040282":[30,79],"HP:0040283":[5,29],"HP:0040284":[1,4],"HP:0040285":[0,0]},"page":{"anchorSlug":"neuronal-ceroid-lipofuscinosis-3","columns":[{"countQualifier":"Onset group unspecified","gene":"CLN3","key":"population-feaa1adacacaed28fecf","label":"CLN3","mondoId":"MONDO:0008767","onsetQualifier":null,"originColumnKey":"MONDO:0008767","originalViews":[{"key":"MONDO:0008767","label":"CLN3","scopeLabel":"Genetic form","sourceScope":null}],"recordKeys":["006351b2364d4f06bd3f038495c435a22b26802b921f3f2cb5d21eb498437a00","145d259cf83a954ca50bb44955c95d0f141f760b197c1caef0296e0cba9486b7","29b7188547555954a8326734c7eb2b2e9f56634fb41d82120f2d108dad88acb5","34050a7ff22eaa0eefd40dc55f66f45241073858c7478ff6d6c155d63df56c74","444d3e228f51d8bfabf559f288322be357b85738ccb3e8719b37541ddf5e773e","49d1bcc442be3f5016c704eb131bd65e32ed57e5170d31b612a7fc5dfd49798d","4b76b8d816a725986447b25c277db13b371c3d66e9b7c6d2e29faabd199750b9","4ec13a42a9991613fdaf32f8f767686aaa4f95df1ac8123e35c68afb4cfd5499","6937a295d7f767426a7b2f2869f44a7a8197de50505bb634ad8d8921ede108ab","69fd2603faa9d2e41c6c155ec2b33df9e0dc3aa71f2942ed58171f737a635a11","6ba4646569ea83efdda8ad5b66afc32fd5d0a766c8f92c8fb4abd024ce437aec","6c426203f86b7c0736654b79254ca6c3929b02daa576f2887532ecf68301a255","6cc70e2e926295bd8e5ef9d7e2a87794af26cc793fb1e36e347f446829b51fd6","6fc9be7e6c8da52184f68c557ef1482307d1dd222d328e2ef5fccadcdea7c6db","70f7a50118a0a7aabb5f9c3ece5ff7132fbdccbe1ea277e66f9f63740c61f484","7a6e2b255bd02770ea703114c8a3b9cd2664ab56a4a434e5779650067b53a260","99d637cd8c59067c510d66dc01922408969f0afd98bf32c3fbbf59d71d5d67ca","9edb0a2b8da8430ddd557a36ec90d0ae50f6c4ad02db0e17659481f2341bbc22","a38890e34659e9152a6e490b03d666525b2e2fa799c32d93ff81f5928b38e1a7","a8e00fc0af8765813ec66b04859fd879c5c29b194431b20ce6234a361e968cde","b9897fb89ee0deab27e319f1fdd5e55c61ba58d14387f9ef9b546201241e849e","cb9ddf19da4beb393805160fff62b173086fbf67c7acb6e3ee99010ecd0f21c4","d32e16d55553195f4ec91b398d2ac09d3a436f8d060eca593858ef7f648188cf","d43fd87e5f5a82dc24d488d7230de2cfa9c75499a16e9a66cae6bcc09b552838","d5765a808b9365b746a4d820be800cc0affe34b56b34804d730dc004ec7a5c3a","e751bb5f3b7483bd34aaa84fd8bef8b54ce2ddac4f5dc381cae6c43ced3470ba","ed2c6e25aae34bd8e1158a6e84beab535978e7f20aa986da1afc6b34c50d43ce","f321178daf1d15ed22fae542eeb8856ae869839e809e525c9fd05388ec15382e","f46f5f396d5fadc1ac72fcb58269cf1eb02d0c45407ba9db3ee99b72cbadd0d3","fc64b50a71640194e8c7d46c1aa1688a36437d06c737f04385080e9ea79bf9a5"],"recordQualifiers":{"006351b2364d4f06bd3f038495c435a22b26802b921f3f2cb5d21eb498437a00":"Onset group unspecified","145d259cf83a954ca50bb44955c95d0f141f760b197c1caef0296e0cba9486b7":"Onset group unspecified","34050a7ff22eaa0eefd40dc55f66f45241073858c7478ff6d6c155d63df56c74":"Onset group unspecified","6937a295d7f767426a7b2f2869f44a7a8197de50505bb634ad8d8921ede108ab":"Onset group unspecified","69fd2603faa9d2e41c6c155ec2b33df9e0dc3aa71f2942ed58171f737a635a11":"Onset group unspecified","70f7a50118a0a7aabb5f9c3ece5ff7132fbdccbe1ea277e66f9f63740c61f484":"Onset group unspecified","9edb0a2b8da8430ddd557a36ec90d0ae50f6c4ad02db0e17659481f2341bbc22":"Onset group unspecified","a38890e34659e9152a6e490b03d666525b2e2fa799c32d93ff81f5928b38e1a7":"Onset group unspecified","f321178daf1d15ed22fae542eeb8856ae869839e809e525c9fd05388ec15382e":"Onset group unspecified"},"scopeLabel":"Genetic form","sourceIds":["OMIM:204200"],"sourceScope":null}],"comparison":{"collapseColumnsLabel":"Show default populations","defaultColumnKeys":["population-feaa1adacacaed28fecf"],"expandColumnsLabel":"Show all source populations","intro":"Features recorded for this MONDO node. Related-node evidence is available through separately scoped comparisons.","primaryFeatureIds":["HP:0001317","HP:0002071","HP:0000739","HP:0002069","HP:0000618","HP:0000518","HP:0002059"],"scopeNoteHtml":"<p>Each column retains its native condition identifier, assessed population and annotation references. Counts are not pooled.</p>"},"coverage":{"countRecords":9,"emptyColumnKeys":[],"hpoRelease":"2026-06-23","narrativeSourceChanges":[],"records":30,"sourceGroups":{"omim":21,"published":9}},"features":[{"hpoId":"HP:0001317","label":"Abnormal cerebellum morphology","primary":true},{"hpoId":"HP:0002071","label":"Abnormality of extrapyramidal motor function","primary":true},{"hpoId":"HP:0000739","label":"Anxiety","primary":true},{"hpoId":"HP:0002069","label":"Bilateral tonic-clonic seizure","primary":true},{"hpoId":"HP:0000618","label":"Blindness","primary":true},{"hpoId":"HP:0000518","label":"Cataract","primary":true},{"hpoId":"HP:0002059","label":"Cerebral atrophy","primary":true},{"hpoId":"HP:0005157","label":"Concentric hypertrophic cardiomyopathy","primary":false},{"hpoId":"HP:0003205","label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0000726","label":"Dementia","primary":false},{"hpoId":"HP:0001260","label":"Dysarthria","primary":false},{"hpoId":"HP:0003208","label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","primary":false},{"hpoId":"HP:0000501","label":"Glaucoma","primary":false},{"hpoId":"HP:0003463","label":"Increased extraneuronal autofluorescent lipopigment","primary":false},{"hpoId":"HP:0002074","label":"Increased neuronal autofluorescent lipopigment","primary":false},{"hpoId":"HP:0001249","label":"Intellectual disability","primary":false},{"hpoId":"HP:0002505","label":"Loss of ambulation","primary":false},{"hpoId":"HP:0000608","label":"Macular degeneration","primary":false},{"hpoId":"HP:0001336","label":"Myoclonus","primary":false},{"hpoId":"HP:0000648","label":"Optic atrophy","primary":false},{"hpoId":"HP:0001300","label":"Parkinsonism","primary":false},{"hpoId":"HP:0000529","label":"Progressive visual loss","primary":false},{"hpoId":"HP:0002361","label":"Psychomotor deterioration","primary":false},{"hpoId":"HP:0000709","label":"Psychosis","primary":false},{"hpoId":"HP:0007663","label":"Reduced visual acuity","primary":false},{"hpoId":"HP:0000546","label":"Retinal degeneration","primary":false},{"hpoId":"HP:0000510","label":"Rod-cone dystrophy","primary":false},{"hpoId":"HP:0001250","label":"Seizure","primary":false},{"hpoId":"HP:0000550","label":"Undetectable electroretinogram","primary":false},{"hpoId":"HP:0001922","label":"Vacuolated lymphocytes","primary":false}],"ledeHtml":"CLN3 disease is an inherited disorder that primarily affects the nervous system. After 4 to 6 years of normal development, children with this condition develop vision impairment, intellectual disability, movement problems, speech difficulties, and seizures, which worsen over time.","mondoId":"MONDO:0008767","node":{"canonicalSlug":"neuronal-ceroid-lipofuscinosis-3","comparisons":[{"documentSha256":"feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069","key":"legacy-cln","kind":"legacy","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/cln.feab7132c1e6efa19316faa9c5b975a6a6317da700f12b5b4c059a18eda6d069.json"},{"documentSha256":"df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3","key":"expanded-cln","kind":"expanded","label":"CLN / Batten disease","memberIds":["MONDO:0008083","MONDO:0008767","MONDO:0008768","MONDO:0008769","MONDO:0009744","MONDO:0009745","MONDO:0010830","MONDO:0011144","MONDO:0012188","MONDO:0012391","MONDO:0012414","MONDO:0012588","MONDO:0012721","MONDO:0013866","MONDO:0014147","MONDO:0016295","MONDO:0017809","MONDO:0019260","MONDO:0019261","MONDO:0019262","MONDO:0030947","MONDO:0850001"],"mondoId":"MONDO:0016295","url":"https://kcjyutqgtpgteszueluf.supabase.co/storage/v1/object/public/community-guides/learn-data/node-comparison-df7e5010cb40de30aba1.df7e5010cb40de30aba1b0d10ff00b9c8a49865234f6a0ea186c9a1493e9aae3.json"}],"contexts":[],"lifecycle":"active","narrative":{"causes":["CLN3 disease is caused by mutations in the CLN3 gene, which provides instructions for making a protein that is found in tissues throughout the body. The CLN3 protein is part of many compartments within cells, including lysosomes, which are cellular compartments that digest and recycle different types of molecules. However, the exact function of the CLN3 protein is unclear. Research has shown that this protein is involved in many cellular processes, but it is uncertain which of them is the primary role of the protein, or if these processes instead represent downstream effects.","It is unclear how mutations in the CLN3 gene lead to the characteristic features of CLN3 disease. One CLN3 gene mutation, found in the vast majority of cases, leads to the production of an abnormally short protein. As a result, the abnormal CLN3 protein is broken down or may interfere with normal cellular processes. Other mutations reduce the amount of normal protein or impair its function. It is not known how loss of this protein causes the signs and symptoms of CLN3 disease.","CLN3 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues leads to the neurological signs and symptoms of CLN3 disease. However, it is unclear how mutations in the CLN3 gene are involved in the buildup of substances in lysosomes."],"causesUrl":"https://medlineplus.gov/genetics/condition/cln3-disease/#causes","contentForm":"summary","matchMethod":"reviewed-binding","name":"CLN3 disease","paragraphs":["CLN3 disease is an inherited disorder that primarily affects the nervous system. After 4 to 6 years of normal development, children with this condition develop vision impairment, intellectual disability, movement problems, speech difficulties, and seizures, which worsen over time.","In children with CLN3 disease, problems with vision often begin between the ages of 4 and 8 years. Vision impairment is caused by a breakdown of the light-sensitive tissue at the back of the eye (retinal degeneration), which worsens with age. People with CLN3 disease are often blind by late childhood or adolescence. Also around age 4 to 8, children with CLN3 disease start to fall behind in school. They have difficulty learning new information and lose previously acquired skills (developmental regression), usually beginning with loss of the ability to speak in complete sentences.","Seizures and movement abnormalities often develop in adolescence in people with CLN3 disease. These abnormalities include muscle rigidity or stiffness, clumsiness, slow or diminished movements (hypokinesia), and a stooped posture. Over time, affected individuals lose the ability to walk or sit independently and require wheelchair assistance. Rarely, people with CLN3 disease develop a distorted view of reality (psychosis) or false perceptions (hallucinations). Some affected individuals have an abnormal heart rhythm (arrhythmia) later in life. Most people with CLN3 disease live into early adulthood.","CLN3 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation \"CLN,\" meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype."],"reviewed":"2020-02","scope":"exact","scopeNote":"","source":"MedlinePlus","sourceRelease":"2026-10-01","upstream":"MedlinePlus Genetics","url":"https://medlineplus.gov/genetics/condition/cln3-disease"},"ownColumnKeys":["population-feaa1adacacaed28fecf"],"publication":"published","relationships":[{"kind":"parent","label":"neuronal ceroid lipofuscinosis","mondoId":"MONDO:0016295","slug":"cln"}],"schemaVersion":1,"searchIndex":"/node-search/manifest.json","sourceHolds":{},"summaryHolds":[{"reason":"native-cross-reference-does-not-establish-scope","source":"MedlinePlus","url":"https://medlineplus.gov/genetics/condition/cln3-disease"}],"translation":"published","articles":[{"articleId":"rarediseases.info.nih.gov/diseases/5897","pageMondoId":"MONDO:0008767","source":"GARD","name":"Neuronal ceroid lipofuscinosis 3","url":"https://rarediseases.info.nih.gov/diseases/5897","relationToPage":"same-condition","coveredMondoIds":["MONDO:0008767"],"status":"validated-exact-source","presentation":"additional-reference","evidence":["existing-offline-scope-validator","automatic-identity-and-attribution"],"reviewed":null,"sourceRelease":"2026-10-25T03:39:35Z","upstream":"GARD:0005897","rawAttribution":"MONDO:0008767","independentCorroborationEstablished":false}]},"records":[{"frequencyKind":"count","key":"006351b2364d4f06bd3f038495c435a22b26802b921f3f2cb5d21eb498437a00","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0001300","is_excluded":false,"label":"Parkinsonism","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"145d259cf83a954ca50bb44955c95d0f141f760b197c1caef0296e0cba9486b7","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0002505","is_excluded":false,"label":"Loss of ambulation","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"29b7188547555954a8326734c7eb2b2e9f56634fb41d82120f2d108dad88acb5","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003463","is_excluded":false,"label":"Increased extraneuronal autofluorescent lipopigment","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"34050a7ff22eaa0eefd40dc55f66f45241073858c7478ff6d6c155d63df56c74","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0002361","is_excluded":false,"label":"Psychomotor deterioration","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"444d3e228f51d8bfabf559f288322be357b85738ccb3e8719b37541ddf5e773e","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000518","is_excluded":false,"label":"Cataract","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"49d1bcc442be3f5016c704eb131bd65e32ed57e5170d31b612a7fc5dfd49798d","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0003205","is_excluded":false,"label":"Curvilinear intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"4b76b8d816a725986447b25c277db13b371c3d66e9b7c6d2e29faabd199750b9","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002074","is_excluded":false,"label":"Increased neuronal autofluorescent lipopigment","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"4ec13a42a9991613fdaf32f8f767686aaa4f95df1ac8123e35c68afb4cfd5499","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000550","is_excluded":false,"label":"Undetectable electroretinogram","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"6937a295d7f767426a7b2f2869f44a7a8197de50505bb634ad8d8921ede108ab","raw":{"aspect":"P","body_system":"metabolic","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0003208","is_excluded":false,"label":"Fingerprint intracellular accumulation of autofluorescent lipopigment storage material","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"69fd2603faa9d2e41c6c155ec2b33df9e0dc3aa71f2942ed58171f737a635a11","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0002069","is_excluded":false,"label":"Bilateral tonic-clonic seizure","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"6ba4646569ea83efdda8ad5b66afc32fd5d0a766c8f92c8fb4abd024ce437aec","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002071","is_excluded":false,"label":"Abnormality of extrapyramidal motor function","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"6c426203f86b7c0736654b79254ca6c3929b02daa576f2887532ecf68301a255","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001336","is_excluded":false,"label":"Myoclonus","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"6cc70e2e926295bd8e5ef9d7e2a87794af26cc793fb1e36e347f446829b51fd6","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000648","is_excluded":false,"label":"Optic atrophy","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"6fc9be7e6c8da52184f68c557ef1482307d1dd222d328e2ef5fccadcdea7c6db","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000709","is_excluded":false,"label":"Psychosis","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"70f7a50118a0a7aabb5f9c3ece5ff7132fbdccbe1ea277e66f9f63740c61f484","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000546","is_excluded":false,"label":"Retinal degeneration","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"7a6e2b255bd02770ea703114c8a3b9cd2664ab56a4a434e5779650067b53a260","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0002059","is_excluded":false,"label":"Cerebral atrophy","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"99d637cd8c59067c510d66dc01922408969f0afd98bf32c3fbbf59d71d5d67ca","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000501","is_excluded":false,"label":"Glaucoma","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"9edb0a2b8da8430ddd557a36ec90d0ae50f6c4ad02db0e17659481f2341bbc22","raw":{"aspect":"P","body_system":"blood","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0001922","is_excluded":false,"label":"Vacuolated lymphocytes","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"count","key":"a38890e34659e9152a6e490b03d666525b2e2fa799c32d93ff81f5928b38e1a7","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0007663","is_excluded":false,"label":"Reduced visual acuity","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"a8e00fc0af8765813ec66b04859fd879c5c29b194431b20ce6234a361e968cde","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0000739","is_excluded":false,"label":"Anxiety","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"b9897fb89ee0deab27e319f1fdd5e55c61ba58d14387f9ef9b546201241e849e","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000510","is_excluded":false,"label":"Rod-cone dystrophy","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"cb9ddf19da4beb393805160fff62b173086fbf67c7acb6e3ee99010ecd0f21c4","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001250","is_excluded":false,"label":"Seizure","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"d32e16d55553195f4ec91b398d2ac09d3a436f8d060eca593858ef7f648188cf","raw":{"aspect":"P","body_system":"cardiovascular","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"TAS","frequency_raw":null,"hpo_id":"HP:0005157","is_excluded":false,"label":"Concentric hypertrophic cardiomyopathy","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"d43fd87e5f5a82dc24d488d7230de2cfa9c75499a16e9a66cae6bcc09b552838","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001317","is_excluded":false,"label":"Abnormal cerebellum morphology","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"d5765a808b9365b746a4d820be800cc0affe34b56b34804d730dc004ec7a5c3a","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001260","is_excluded":false,"label":"Dysarthria","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"e751bb5f3b7483bd34aaa84fd8bef8b54ce2ddac4f5dc381cae6c43ced3470ba","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000608","is_excluded":false,"label":"Macular degeneration","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"ed2c6e25aae34bd8e1158a6e84beab535978e7f20aa986da1afc6b34c50d43ce","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000726","is_excluded":false,"label":"Dementia","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"count","key":"f321178daf1d15ed22fae542eeb8856ae869839e809e525c9fd05388ec15382e","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"PCS","frequency_raw":"1/1","hpo_id":"HP:0000529","is_excluded":false,"label":"Progressive visual loss","onset_id":null,"reference":"PMID:7887420","source_release":"2026-06-23"},"sourceGroups":["published"]},{"frequencyKind":"reported","key":"f46f5f396d5fadc1ac72fcb58269cf1eb02d0c45407ba9db3ee99b72cbadd0d3","raw":{"aspect":"P","body_system":"nervous_system","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0001249","is_excluded":false,"label":"Intellectual disability","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]},{"frequencyKind":"reported","key":"fc64b50a71640194e8c7d46c1aa1688a36437d06c737f04385080e9ea79bf9a5","raw":{"aspect":"P","body_system":"eye","disease_id":"OMIM:204200","disease_name":"Ceroid lipofuscinosis, neuronal, 3","evidence":"IEA","frequency_raw":null,"hpo_id":"HP:0000618","is_excluded":false,"label":"Blindness","onset_id":null,"reference":"OMIM:204200","source_release":"2026-06-23"},"sourceGroups":["omim"]}],"referenceLabels":{},"references":{"causeHtml":"<p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln3-disease\" rel=\"noreferrer\">MedlinePlus</a></p><p class=\"section-source\">Source: <a href=\"https://rarediseases.info.nih.gov/diseases/5897\" rel=\"noreferrer\">GARD</a></p><p class=\"section-source\">Source: <a href=\"https://monarchinitiative.org/MONDO:0008767\" rel=\"noreferrer\">MONDO</a></p><details class=\"deep-dive\"><summary>Narrative source and scope</summary><dl><dt>Content</dt><dd>summary</dd><dt>Scope</dt><dd>exact</dd><dt>Match method</dt><dd>reviewed-binding</dd><dt>Upstream attribution</dt><dd>MedlinePlus Genetics</dd></dl></details>","identityNote":"MONDO identifies this node. Native source populations, annotation references and qualified comparison views retain their original scopes.","importantHtml":""},"sections":[{"bodyHtml":"<p>CLN3 disease is an inherited disorder that primarily affects the nervous system. After 4 to 6 years of normal development, children with this condition develop vision impairment, intellectual disability, movement problems, speech difficulties, and seizures, which worsen over time.</p><p>In children with CLN3 disease, problems with vision often begin between the ages of 4 and 8 years. Vision impairment is caused by a breakdown of the light-sensitive tissue at the back of the eye (retinal degeneration), which worsens with age. People with CLN3 disease are often blind by late childhood or adolescence. Also around age 4 to 8, children with CLN3 disease start to fall behind in school. They have difficulty learning new information and lose previously acquired skills (developmental regression), usually beginning with loss of the ability to speak in complete sentences.</p><p>Seizures and movement abnormalities often develop in adolescence in people with CLN3 disease. These abnormalities include muscle rigidity or stiffness, clumsiness, slow or diminished movements (hypokinesia), and a stooped posture. Over time, affected individuals lose the ability to walk or sit independently and require wheelchair assistance. Rarely, people with CLN3 disease develop a distorted view of reality (psychosis) or false perceptions (hallucinations). Some affected individuals have an abnormal heart rhythm (arrhythmia) later in life. Most people with CLN3 disease live into early adulthood.</p><p>CLN3 disease is one of a group of disorders known as neuronal ceroid lipofuscinoses (NCLs), which may also be collectively referred to as Batten disease. All these disorders affect the nervous system and typically cause worsening problems with vision, movement, and thinking ability. The different NCLs are distinguished by their genetic cause. Each disease type is given the designation &quot;CLN,&quot; meaning ceroid lipofuscinosis, neuronal, and then a number to indicate its subtype.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln3-disease\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"overview","title":"Overview"},{"bodyHtml":"<p>CLN3 disease is caused by mutations in the CLN3 gene, which provides instructions for making a protein that is found in tissues throughout the body. The CLN3 protein is part of many compartments within cells, including lysosomes, which are cellular compartments that digest and recycle different types of molecules. However, the exact function of the CLN3 protein is unclear. Research has shown that this protein is involved in many cellular processes, but it is uncertain which of them is the primary role of the protein, or if these processes instead represent downstream effects.</p><p>It is unclear how mutations in the CLN3 gene lead to the characteristic features of CLN3 disease. One CLN3 gene mutation, found in the vast majority of cases, leads to the production of an abnormally short protein. As a result, the abnormal CLN3 protein is broken down or may interfere with normal cellular processes. Other mutations reduce the amount of normal protein or impair its function. It is not known how loss of this protein causes the signs and symptoms of CLN3 disease.</p><p>CLN3 disease, like other NCLs, is characterized by the accumulation of proteins and other substances in lysosomes. These accumulations occur in cells throughout the body; however, nerve cells seem to be particularly vulnerable to their effects. The accumulations can cause cell damage leading to cell death. The progressive death of nerve cells in the brain and other tissues leads to the neurological signs and symptoms of CLN3 disease. However, it is unclear how mutations in the CLN3 gene are involved in the buildup of substances in lysosomes.</p><p class=\"section-source\">Source: <a href=\"https://medlineplus.gov/genetics/condition/cln3-disease/#causes\" rel=\"noreferrer\">MedlinePlus</a></p>","key":"causes","title":"Causes"}],"sharedSources":[],"slug":"neuronal-ceroid-lipofuscinosis-3","sourceDocuments":[{"name":"MedlinePlus: CLN3 disease","reviewed":"2020-02","source_release":"2026-10-01","url":"https://medlineplus.gov/genetics/condition/cln3-disease"},{"name":"GARD: Neuronal ceroid lipofuscinosis 3","reviewed":null,"source_release":"2026-10-25T03:39:35Z","url":"https://rarediseases.info.nih.gov/diseases/5897"},{"name":"MONDO: neuronal ceroid lipofuscinosis 3","reviewed":null,"source_release":"releases/2026-10-06","url":"https://monarchinitiative.org/MONDO:0008767"}],"sourceNote":"","synonyms":["ceroid lipofuscinosis, neuronal, 3","ceroid lipofuscinosis, neuronal, type 3","CLN3","CLN3 disease, juvenile","CLN3 neuronal ceroid lipofuscinosis","Juvenile CLN3 Disease","neuronal ceroid lipofuscinosis 3","neuronal ceroid lipofuscinosis caused by mutation in CLN3","neuronal ceroid lipofuscinosis type 3","Spielmeyer Sjogren disease","Vogt Spielmeyer disease"],"takeawayHtml":"","title":"neuronal ceroid lipofuscinosis 3"},"schemaVersion":1}
